BioNTech (BNTX) CEO Sahin Ugur Sells $3.5M of Stock

Sahin Ugur, the Chief Executive Officer of BioNTech SE (NasdaqGS: BNTX), sold 36,209 shares on October 9, 2026, at a price of $95.37 each. The total value of this transaction was approximately $3.45 million. This sale was part of a planned transaction.

Inside Sahin Ugur's Trade

Ugur's recent sale adds to a series of transactions in which he has sold shares of BioNTech. This was his fourth sale since September 28, 2026, where he sold 61,000 shares, followed by sales of 66,000 shares and 93,000 shares on September 30 and October 6, respectively. His activity reflects a consistent pattern of selling shares in the company.

Other Institutional Activity in BioNTech

FMR, LLC increased its stake in BioNTech by 1,862,406 shares, bringing its total to 7,571,805 shares valued at about $664.1 million. In contrast, Flossbach von Storch SE reduced its holdings by 1,454,037 shares, resulting in 2,226,138 shares worth around $195.3 million. T. Rowe Price Investment Management, Inc. also trimmed its position by 3,790,671 shares, ending with 2,065,456 shares valued at approximately $181.2 million.

BioNTech SE Stock Down 1.9%

As of October 16, 2026, BioNTech shares are trading around $88.52, which is 10.4% below the 50-day moving average of about $98.85. The stock is also about 28.6% below its 52-week high of $124.00. Analysts see potential upside, with a target mean price of $117.05, suggesting the stock is currently undervalued compared to this target.

Recent Earnings

BioNTech reported trailing twelve-month revenue of approximately $2.65 billion. However, the company faced a significant revenue decline of 59.5% year-over-year, and its net margin stands at -63.6%. The next earnings announcement is scheduled for November 3, 2026.

Insider Buying and Selling at BioNTech SE

In the days leading up to Ugur's sale, he executed several transactions. On October 7, 2026, he sold 24,000 shares at an average price of $95.86, valued at roughly $2.3 million. Earlier, he sold 93,000 shares on October 6, 2026, totaling about $9.03 million. These transactions indicate a trend of selling shares rather than buying.

Analysts Set New Price Targets

On October 7, 2026, Morgan Stanley maintained its Overweight rating on BioNTech with a price target of $114.00. This follows earlier ratings where Citigroup and Canaccord Genuity maintained Buy ratings with targets of $125.00 and $136.00, respectively. The consensus among analysts is a Buy rating, with a mean price target of $117.05 based on 20 opinions.

About BioNTech

BioNTech SE is a biotechnology company based in Mainz, Germany. It focuses on developing and commercializing immunotherapies, particularly mRNA vaccines, including its well-known BNT162 vaccine for SARS-CoV-2. The company's recent stock activity and financial performance are closely watched as it navigates the evolving healthcare landscape.

Bottom Line

Investors should monitor BioNTech's upcoming earnings report on November 3, 2026. The recent insider selling by CEO Sahin Ugur adds context to the company's stock performance and market perception.